NOVOMEDLINK™
  1. Diabetes Care

    GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  2. Levemir®

    (insulin detemir [rDNA origin] injection)

  3. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  4. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  5. Victoza®

    (liraglutide [rDNA origin] injection)

  6. Hormone Therapy

    Activella®

    (estradiol/norethindrone acetate tablets)

  7. Vagifem®

    (estradiol vaginal tablets)

  8. Growth Hormone

    Norditropin®

    (somatropin (rDNA origin) injection)

  9. Hemostasis

    NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

  10. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

references

  1. Data on file, Novo Nordisk, Inc., Princeton, NJ.
  2. IMS Health Inc. IMS MIDAS (12 months ending September 2009).
  3. Levemir® [package insert]. Princeton, NJ: Novo Nordisk Inc; 2009.
  4. Rašlová K, Bogoev M, Raz I, Leth G, Gall M-A, Hâncu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66(2):193-201.
  5. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes [abstract]. European Association for the Study of Diabetes 43rd Annual Meeting, Amsterdam, The Netherlands, September 17-21, 2007.
  6. Home P, Bartley P, Russell-Jones D; on behalf of the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Diabetes Care. 2004;27(5):1081-1087.
  7. Dornhorst A, Lüddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61(3):523-528.
  8. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord. 2004;28(suppl 2):S23-S28.
  9. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-1620.
  10. Meneghini L, Koenen C, Rojas P. Efficacy and safety of insulin detemir in a large cohort of patients with type 2 diabetes using a simplified self-adjusted dosing guideline—results of the PREDICTIVE™ 303 study. Oral presentation presented at: American Diabetes Association 67th Annual Sessions; June 2007; Chicago, IL. Oral presentation 197.
  11. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9(3):418-427.
  12. Hermansen K, Davies M, Derezinski T, Martinez Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274.
  13. Data on file. NDA21-536. Novo Nordisk, Inc., Princeton, NJ.
  14. Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26(4):531-540.
  15. American College of Endocrinology. ACE road map. http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf. Accessed July 24, 2007.
  16. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318(19):1231-1239.
  17. Korytkowski M, Bell D, Jacobsen C, Suwannasari R, for the FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
  18. IMS Health Inc. IMS MIDAS (Q1 2007, worldwide report).
  19. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-496.
  20. Klein O, Lynge J, Endhal L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9(3):290-299.
  21. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569-1581.
  22. Selam J-L, Koenien C, Rojas P, Meneghini L. Self-tirtrated insulin detemir helps insulin-naïve patients to achieve glycemic targets. Poster presented at American Diabetes Association 67th Annual Sessions, June 22-26, 2007, Chicago, IL. Poster 2259.
  23. American Association of Clinical Endocrinologists. State of Diabetes in America™. www.aace.com/public/awareness/stateofdiabetes/. Accessed October 25, 2007.
  24. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20.
  25. Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2-3):307-335.
  26. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583-588.
  27. Data on file. Novo Nordisk Inc, Princeton, NJ.
  28. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21(7):769-775.
  29. Stratton IM, Adler AI, Neil AW, et al, on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(August 12):405-412.
  30. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
  31. American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
  32. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2002 update. http://www.aace.com/pub/pdf/guidelines/diabetes_2002.pdf. Accessed January 13, 2006.
  33. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(26):881-885.
  34. American Diabetes Association. Intensive Diabetes Management. 3rd ed. Alexandria, VA: American Diabetes Association; 2003.
  35. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-444.
  36. Raskin P, Bode B, Marks JB, et al. Insulin aspart (IAsp) is as effective in continuous subcutaneous insulin infusion as in multiple daily injections for patients with type 2 diabetes. Diabetes. 2001;50(suppl 2):A128. Abstract 515P.
  37. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001;24(1):69-72.
  38. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23(2):78-86.
  39. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997;20(10):1612-1614.
  40. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8(1):58-66.
  41. Raskin P, Allen E, Hollander P, et al; for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265.
  42. Data on file. Novo Nordisk Inc, Princeton, NJ.
  43. IMS Health Inc. Q3 2005 IMS formulary focus data, interstudy lives. Valid as of December 2006.
  44. Data on file. Novo Nordisk Inc, Princeton, NJ.
  45. Activella® [package insert]. Princeton, NJ: Novo Nordisk Inc; 2009.
  46. Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, eds. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:1598.
  47. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause. 2007;14(3):357-369.
  48. What is Hemophilia? In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:1-1 to 1-24.
  49. Bleeding Episodes. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:3-1 to 3-29.
  50. Complications of Hemophilia. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:4-1 to 4-25.
  51. Arun B, Kessler CM. Clinical Manifestations and Therapy of the Hemophilias. In: Colan RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:815-824.
  52. Feinstein DI. Inhibitors in Hemophilia. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1904-1911.
  53. Dental and Oral Care. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:5-1 to 5-13.
  54. Feinstein DI. Inhibitors of Blood Coagulation. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000: 1963-1983.
  55. Physical Activity. In: Butler RB, Crudder SO, Riske B, Toal S, eds. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families with a New Diagnosis of Hemophilia. Atlanta, Ga: Centers for Disease Control and Prevention; 2001:6-1 to 6-16.
  56. National Hemophilia Foundation. "Do the 5" Program. Available at: http://www.hemophilia.org/programs/npp/npp.htm. Accessed June 6, 2006.
  57. DiMichele DM. Inhibitors in hemophilia: A primer. In: Treatment of Hemophilia. 4th ed. Montreal, Quebec: World Federation of Hemophilia; April 2008.
  58. Ewing, NP. Induction of immune tolerance, the future of the Registry. Vox Sang. 1996;70(suppl 1):47-51.
  59. Mariani, G Ghiradini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Thromb Haemost. 1994;72:155-158.
  60. Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII–a critical appraisal. Haemophilia. 2006;12(1):19-27.
  61. Lusher JM, Roberts HR, Davignon G, et al; for rFVlla Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor Vlla in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4:790-798.
  62. Data on file, Novo Nordisk Inc., Princeton, NJ.
  63. Sakai T, Lund-Hansen T, Thim L, Kisiel W. The gamma-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor. J Biol Chem 1990; 265: 1890-1894.
  64. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958-965.
  65. Hoffman M, Monroe DM, Roberts HR. Activated Factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9 (suppl 1):s61-s65.
  66. Data on file. Integrated Summary of Safety. [1997:103]. Novo Nordisk Inc.
  67. Nicolaisen EM, Hansen LL, Poulsen F. Immunological aspects of recombinant factor VII (rFVIIa) in clinical use. Thromb Haemost. 1996;76:200-204.
  68. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.
  69. Woolhouse MEJ, Gowtage-Sequeria S, Evans B. Quantitative analysis of the characteristics of emerging and re-emerging human pathogens (T-16). Available at: www.foresight.gov.uk. Accessed May 3, 2006.
  70. National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2004 Chartbook on Cardiovascular, Lung, and Blood Diseases. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD. 2004:5.
  71. National Hemophilia Federation. National Hemophilia Federation bleeding page. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=43&contentid=39&rptname=bloodsafety. Accessed July 17, 2008.
  72. Medical and Scientific Advisory Council. MASAC Recommendation #169: Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission.
  73. Brackmann H-H, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol. 1998;61(suppl 63):18-23.
  74. Giangrande P. Acquired Hemophilia: Treatment of Hemophilia No. 38 [monograph]. Montreal, Quebec: World Federation of Hemophilia; 2005.
  75. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45(3):200-203.
  76. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
  77. Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol. 2000;22:275-278.
  78. Cohen AJ, Kessler CM. Acquired inhibitors. Bailleres Clin Haematol. 1996;9:331-354.
  79. NovoSeven [package insert]. Princeton, NJ: Novo Nordisk Inc; 2006.
  80. Collins PW, Hirsch S, Baglin TP, et al; for UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-1877.
  81. Anderson A, Forsyth A. Playing it safe: bleeding disorders, sports and exercise. New York: National Hemophilia Foundation, 2005.
  82. Nursing Group of Hemophilia Region VI. Emergency care for patients with hemophilia. Last Update 2003. Available at: http://www.hemophiliaemergencycare.com/index.html Accessed April 28, 2008.
  83. Ding C, Cicuttini F, Scott F, et al. Knee structural alteration and BMI: a cross-sectional study. Obes Res 2005; 13:350-61.
  84. Messier SP, Gutekunst DJ, Davis C, et al. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum 2005; 52:2026-32.
  85. NovoSeven® RT [package insert]. Princeton, NJ: Novo Nordisk Inc.; 2008.
  86. FEIBA® VH (anti-inhibitor coagulant complex, vapor heated) package insert. Westlake Village, CA: Baxter Healthcare Corporation; 2005.
  87. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5: 893-900.
  88. Mariani G, Testa MG, Di Paolantonia T, Molskov Bech R, Medner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131-136.
  89. Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118:689-700.
  90. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13:451-461.
  91. Roberts HR, Monroe DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41(suppl 1):101-108.
  92. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol. 1994;47:208-217.
  93. Rodriguez-Merchan ED, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia. 2004;10:22-29.
  94. Centers for Disease Control and Prevention. Bleeding Disorders. Available at: http://www.cdc.gov/ncbddd/hbd/hemophilia.htm. Accessed July 17, 2008.
  95. Data on file. Correspondence from crude material manufacturers. Novo Nordisk Inc, Princeton, NJ.
  96. Data on file. Study report/KLIM/PD/9/USA. Novo Nordisk Inc, Princeton, NJ.
  97. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause. 1999;6:282-289.
  98. Johnson JV, Davidson M, Archer D, Bachmann G. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause. 2002;9:16-22.
  99. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007;10:120-131.
  100. Data on file. CTR. Novo Nordisk Inc, Princeton, NJ. Trial ID: ALD-1537.
  101. Danne T, Datz N, Endahl L, et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes. 2008;9(6):554-560.
  102. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
  103. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008,20(11):1976-1987.
  104. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-805.
  105. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; for the PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52.
  106. Jellinger PS, Davidson JA, Blonde L, et al; ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13(3):260-268.
  107. Selam J-L, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin. 2008;24(1):11-20.
  108. Philis-Tsimikas A, Koenen C, Pederson CB, Thorsteinsson B. Use of insulin detemir once-daily results in less weight gain compared with the use of NPH insulin, particularly in obese subjects with type 2 diabetes [abstract 0979]. Diabetologia. 2007;50(suppl 1):S404.
  109. Meneghini L, Koenen C, Weng W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab. 2007;9(6):902-913.
  110. Rissler J, Jørgensen C, Rye Hansen M, Hansen N-A. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2217-2222.
  111. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23(2):78-86.
  112. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007;9(6):517-521.
  113. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Tech. 2008;2(3):450-455.
  114. Weinzimer SA, Ternard C, Howard C, et al; for the Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31(2):210-215.
  115. Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23(12):3209-3214.
  116. Khutsoane D, Sharma SK, Almustafa M, et al; for the PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222.
  117. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 70/30 twice daily; a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19(5):393-399.
  118. Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE™ study. Diabetes Obes Metab. 2009;11:623-631.
  119. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999-1005.
  120. Slieker LJ, Brooke GS, DiMarchi RD, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1R receptor more than for the insulin receptor. Diabetologia. 1997;40(suppl 2):S54-S61.
  121. Lantus® [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2007.
  122. Kohn WD, Micanovic R, Myers SL, et al. pl-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides. 2007;28(4):935-948.
  123. Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52(12):2507-2512.
FlexPen®, GlucaGen®, HypoKit®, Levemir®, NovoFine®, and NovoLog® are registered trademarks and NovoMedLink™ is a trademark of Novo Nordisk A/S. Norditropin® and NovoSeven® are registered trademarks of Novo Nordisk Health Care AG. Activella® and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.